Incyte Corporation (NASDAQ:INCY) insider Paul Trower sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $138.41, for a total value of $415,230.00. Following the completion of the transaction, the insider now directly owns 14,853 shares of the company’s stock, valued at $2,055,803.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Paul Trower also recently made the following trade(s):

  • On Friday, August 4th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The stock was sold at an average price of $125.25, for a total value of $375,750.00.
  • On Wednesday, July 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The stock was sold at an average price of $126.18, for a total value of $378,540.00.

Shares of Incyte Corporation (NASDAQ INCY) traded down 1.12% during midday trading on Thursday, reaching $134.34. The company’s stock had a trading volume of 1,421,480 shares. The stock’s market capitalization is $27.63 billion. The stock has a 50-day moving average price of $129.28 and a 200 day moving average price of $130.33. Incyte Corporation has a 52 week low of $77.58 and a 52 week high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. During the same quarter in the prior year, the business posted $0.18 earnings per share. Incyte Corporation’s revenue was up 32.5% on a year-over-year basis. Equities analysts forecast that Incyte Corporation will post ($0.86) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/07/insider-selling-incyte-corporation-incy-insider-sells-3000-shares-of-stock.html.

Large investors have recently made changes to their positions in the stock. Gs Investments Inc. bought a new position in Incyte Corporation during the second quarter valued at about $3,777,000. Lord Abbett & CO. LLC raised its holdings in Incyte Corporation by 40.6% during the second quarter. Lord Abbett & CO. LLC now owns 457,455 shares of the biopharmaceutical company’s stock valued at $57,598,000 after buying an additional 132,127 shares in the last quarter. Ashford Capital Management Inc. raised its holdings in Incyte Corporation by 2.2% during the second quarter. Ashford Capital Management Inc. now owns 101,937 shares of the biopharmaceutical company’s stock valued at $12,835,000 after buying an additional 2,156 shares in the last quarter. Toronto Dominion Bank raised its holdings in Incyte Corporation by 21.3% during the second quarter. Toronto Dominion Bank now owns 57,584 shares of the biopharmaceutical company’s stock valued at $7,250,000 after buying an additional 10,122 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in Incyte Corporation during the second quarter valued at about $403,000. Institutional investors and hedge funds own 91.06% of the company’s stock.

A number of equities analysts have recently weighed in on INCY shares. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price target on shares of Incyte Corporation in a report on Thursday, May 18th. Cowen and Company reissued a “buy” rating on shares of Incyte Corporation in a report on Monday, May 15th. J P Morgan Chase & Co set a $149.00 price target on Incyte Corporation and gave the stock a “buy” rating in a report on Thursday, May 18th. Credit Suisse Group reissued a “buy” rating on shares of Incyte Corporation in a report on Saturday, June 10th. Finally, BidaskClub raised Incyte Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $140.16.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.